An actinium-based backup and Werner helicase inhibitor are notable absences.

A new phase 3, Manifest-3, will start in April to support US filing.

Two new PD-(L)1 x VEGF projects have entered the clinic.

Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.

A more comprehensive dataset on JANX007 sends the group’s stock down.

An in vivo Car-T produced a 100% response rate – in three patients.

The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.

But Perspective sinks again.

But the ESMO discussant recommends against widespread use in hormone-sensitive disease.

Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.